![Page 1: Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:1849-60](https://reader035.vdocuments.us/reader035/viewer/2022070400/56649f055503460f94c19ab8/html5/thumbnails/1.jpg)
Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:1849-60
![Page 2: Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:1849-60](https://reader035.vdocuments.us/reader035/viewer/2022070400/56649f055503460f94c19ab8/html5/thumbnails/2.jpg)
Design and eligibility criteria of primary prevention trials
Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:1849-60
![Page 3: Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:1849-60](https://reader035.vdocuments.us/reader035/viewer/2022070400/56649f055503460f94c19ab8/html5/thumbnails/3.jpg)
Serious vascular events in primary prevention trials-proportional effects of aspirin allocation
Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:1849-60
![Page 4: Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:1849-60](https://reader035.vdocuments.us/reader035/viewer/2022070400/56649f055503460f94c19ab8/html5/thumbnails/4.jpg)
Serious vascularevents in primary
preventionTrials-subgroup
analyses
ATT Collaboration. Lancet 2009;373:1849-60
![Page 5: Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:1849-60](https://reader035.vdocuments.us/reader035/viewer/2022070400/56649f055503460f94c19ab8/html5/thumbnails/5.jpg)
Comparison of proportional and absolute effects of aspirin in primary and secondary prevention trials
Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:1849-60
![Page 6: Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:1849-60](https://reader035.vdocuments.us/reader035/viewer/2022070400/56649f055503460f94c19ab8/html5/thumbnails/6.jpg)
Selected outcomes in primary
and secondary prevention
trials of aspirin, by sex
ATT Collaboration. Lancet 2009;373:1849-60
![Page 7: Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:1849-60](https://reader035.vdocuments.us/reader035/viewer/2022070400/56649f055503460f94c19ab8/html5/thumbnails/7.jpg)
Stroke subtypes in primary and
secondary prevention trials
ATT Collaboration. Lancet 2009;373:1849-60
![Page 8: Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:1849-60](https://reader035.vdocuments.us/reader035/viewer/2022070400/56649f055503460f94c19ab8/html5/thumbnails/8.jpg)
Mortality by cause in primary prevention trials
Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:1849-60
![Page 9: Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:1849-60](https://reader035.vdocuments.us/reader035/viewer/2022070400/56649f055503460f94c19ab8/html5/thumbnails/9.jpg)
Rate ratios (95% CI) associated with risk factors for selected outcomes in people with no known
vascular disease in primary prevention trials
Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:1849-60
![Page 10: Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:1849-60](https://reader035.vdocuments.us/reader035/viewer/2022070400/56649f055503460f94c19ab8/html5/thumbnails/10.jpg)
Predicted 5-year absolute eff ects of
allocation to aspirin in different categories of
age and sex in theprimary and
secondary prevention trials (ignoring non-vascular mortality)
ATT Collaboration. Lancet 2009;373:1849-60
![Page 11: Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:1849-60](https://reader035.vdocuments.us/reader035/viewer/2022070400/56649f055503460f94c19ab8/html5/thumbnails/11.jpg)
Predicted 5-year absolute effects of allocation to aspirin in the primary
prevention trials in different categories of
5-year risk (if untreated)of coronary heart disease
(CHD) (ignoring non-vascular mortality)
ATT Collaboration. Lancet 2009;373:1849-60